• Newly diagnosed Multiple Myeloma according to the IMWG criteria published in 2014.

∙ For cohort A, patients will ≤ 70 years of age.

‣ For the cohorts B and C, patients will be ≤ 80 years of age.

• Measurable disease at screening per IMWG, defined as any of the following:

∙ Serum M-protein level ≥ 1 g/dL or urine M-protein level ≥ 200 mg/24 hours; or

‣ Light chain MM without measurable disease in the serum or urine: serum free light chain ≥ 10 mg/dL and abnormal serum free light chain ratio.

• Note: Local laboratory results may be used to establish measurable disease at screening if the results are ≥ 125% of requirements.

• Only participants who are candidates to receive either D-VRd or Isa-VRd induction regimens, as determined by the investigator, should be considered for this study.

• Male or female aged 18 years or older and has capacity to give informed consent.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate hematological function defined as the following:

‣ Hemoglobin count ≥ 7.5 g/dL (without any red blood cell \[RBC\] transfusion within 7 days prior to the test result; use of recombinant human erythropoietin is permitted).

⁃ Absolute neutrophil count (ANC) ≥ 500/μL (without non-PEGylated myeloid growth factor support within 7 days or PEGylated myeloid growth factor support within 14 days prior to the test result).

⁃ Platelet count ≥ 75,000/μL (unless secondary to bone marrow or spleen involvement of MM, in which platelet count ≥ 50,000/μL is permitted) without any platelet cell transfusion within 7 days prior to the test result. Bone marrow involvement by MM is demonstrated by bone marrow aspiration or biopsy. Spleen involvement by MM is demonstrated by splenomegaly.

⁃ Absolute lymphocyte count (ALC) ≥ 100/μL.

⁃ PTT/PT/INR \< 1.5x upper limit of normal (ULN), unless on a stable dose of anticoagulant for a thromboembolic even (subjects with a history of thromboembolic stroke or history of Grade 2 or greater hemorrhage within 1 year are excluded.

• Adequate renal, hepatic, pulmonary, and cardiac function defined as the following:

‣ Estimated glomerular filtration rate (eGFR) (as estimated by Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] equation \[Section 12.14\]) ≥ 45 mL/min.

⁃ Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.

⁃ Total bilirubin ≤ 1.5 mg/dL, except in participants with Gilbert's syndrome or documented MM liver or pancreatic involvement where ≤ 3 x ULN is permitted.

⁃ Cardiac ejection fraction ≥ 45% with no evidence of clinically significant pericardial effusion as determined by echocardiogram (ECHO). Multigated acquisition (MUGA) scan may be used if an ECHO is not available at the site.

⁃ No evidence of Grade 2 or higher (per National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version \[v\]5.0) pleural effusion or ascites (participants with Grade 1 pleural effusion or ascites are eligible).

⁃ Baseline oxygen saturation \>92% on room air.

• Females of childbearing potential must have a medically supervised negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential; refer to Section 12.2).

• Willing to comply with and able to tolerate study procedures, including consent to participate in separate Long-term Safety Follow-up lasting up to 15 years per authorities´ guidance.